Market Overview

Janney Raises OncoCyte's Fair Value Target From $2 To $4 Due To Encouraging Data And Commercial Sales In 2019, Which Means Further Upside Is Possible To Their 2023 Estimate, Representing 125% Growth


This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for OCX

Feb 2019PiperJaffrayInitiates Coverage OnOverweight
Jul 2018BenchmarkAssumesBuy
Feb 2017Chardan CapitalInitiates Coverage OnBuy

View More Analyst Ratings for OCX
View the Latest Analyst Ratings

Posted-In: Analyst Color Price Target Analyst Ratings Trading Ideas


Related Articles (OCX)

Nonprofit Detroit Blockchain Center Launches With Education, Advocacy, Development Mission

40% Of Student Borrowers Expected To Default In Next 5 Years